SCGB3A2 and pulmonary fibrosis: Both mouse and human recombinant SCGB3A2 proteins exhibited similar levels of anti-fibrotic activity when intravenously administered to mice in the BLM-induced pulmonary fibrosis model, suggesting that SCGB3A2 may be clinically relevant to treat pulmonary fibrosis in humans [18].